A Trial Lists Safety Outcomes: What Events Were Counted and When

By the Regenerative Evidence Guide Team

What “Safety Outcomes” Means on a Trial Listing

When a clinical trial lists safety outcomes, it is reporting adverse events. These are unwanted medical events that happened to participants during a set period of the research, whether or not they were judged to be related to the study. To read that list well, you need to know three things: which kinds of events were counted, over what time window, and how researchers collected them. This guide shows you where to find each one and which questions to ask.

This page focuses on the adverse event tables in a trial’s posted results. For a separate look at individual reports, see our guide to adverse event reports and safety evidence. If you are new to study records, start with how to read a clinical trial record.

By Regenerative Evidence Guide Editorial Team. Updated September 23, 2026.

If You Already Had a Procedure and Feel Unwell

This article is for reading research. It cannot assess symptoms. If you have new or worsening symptoms after any injection, infusion, or procedure, contact a licensed clinician promptly. If it is an emergency, call your local emergency number right away. Reading a trial listing should never delay care.

The Three Safety Tables in Posted Results

The official ClinicalTrials.gov checklist for researchers describes three adverse event tables:

• All-Cause Mortality: all deaths from any cause in each group. This table is required for studies with a primary completion date on or after January 18, 2017.
• Serious Adverse Events: every serious event in each group. ClinicalTrials.gov defines a serious adverse event as one that results in death, is life-threatening, requires or extends a hospital stay, causes ongoing or significant incapacity or major disruption to normal life, or causes a birth defect. An event can also count as serious if it puts the participant in danger or needs medical or surgical care to prevent one of those results.
• Other (Not Including Serious) Adverse Events: non-serious events that happened more often than a frequency threshold the researchers chose. That threshold can be no higher than 5 percent of participants in any group.

That last point matters. A non-serious event that happened to fewer people than the chosen threshold may not appear in the “Other” table at all.

If a study is marked completed but has no results section, see our guide on completed trials with missing results.

Time Frame: When Events Were Counted

For studies with a primary completion date on or after January 18, 2017, results must include a Time Frame. This is the specific period during which adverse events were assessed or collected. ClinicalTrials.gov asks researchers to describe it from the participant’s point of view, such as “8 weeks after participant received first dose,” rather than “end of study.”

Why this matters to you:

• An event that happened after the counting window ended will not be in the table.
• A short window can miss problems that take longer to appear.
• A vague time frame makes it hard to compare one study with another.

For how a study’s plan and its posted results relate, see our guide on study protocols and study results.

How Events Were Collected

For studies with a primary completion date on or after January 18, 2017, researchers must state their collection approach. ClinicalTrials.gov separates two methods:

• Systematic assessment: events are actively asked about, for example with a questionnaire.
• Non-systematic assessment: events are unsolicited, meaning they are recorded when participants bring them up.

Two studies that used different methods did not gather events the same way. Keep that in mind before comparing their event counts.

Also check the number at risk. This is how many people in each group were assessed and could have had an event. It is the bottom half of any fraction you read. The checklist also asks for information about how that number was determined.

Myth Versus Reality

• Myth: Every event on the list was caused by the treatment. Reality: The tables include events linked in time to the research, whether or not they were considered related to taking part.
• Myth: If an event is not listed, it never happened. Reality: Non-serious events below the reporting threshold, and events outside the time frame, may not appear.
• Myth: Fewer listed events means a safer treatment. Reality: A count only makes sense next to how many people were assessed, for how long, and how events were collected.
• Myth: Events in the treatment group tell the whole story. Reality: Results are reported by group, so compare the treatment group with any comparison group. For background, see our guide to randomization, blinding, and placebos.

Evidence Limits: What a Safety Table Cannot Tell You

• It cannot predict your personal risk. Results describe the groups studied, not any one person.
• It cannot show what happened after the stated time frame.
• It cannot show whether a product works. Safety tables are separate from the outcome measures researchers use to judge effects. See our guide to clinical study endpoints.
• It does not describe safety oversight during the study. For that topic, see our guide to data safety monitoring in clinical research.
• It may use technical terms. Researchers can name events using a standard medical dictionary, such as MedDRA, so terms may sound more clinical than everyday words.

A Listing Is Not an Approval

FDA states that being listed in the ClinicalTrials.gov database does not mean a product is legally marketed. The same is true when a firm has registered with FDA and listed its product. FDA also says unapproved regenerative medicine products require FDA oversight in a clinical trial before approval, and it has received reports of blindness, tumor formation, infections, and other harms linked to unapproved products. For more, see how to check FDA status and trial registration and what an “FDA registered” claim means.

Conversation Worksheet: Questions About a Trial’s Safety Results

Bring this list to a licensed clinician, or use it when you read a study record yourself.

1. What is the exact Time Frame for adverse event collection, and does it cover the period I care about?
2. Were events collected systematically (actively asked about) or non-systematically (unsolicited)?
3. How many people were at risk in each group, and how does that compare with how many enrolled?
4. What frequency threshold was used for the “Other” adverse events table?
5. Does the record include an All-Cause Mortality table?
6. Were any serious adverse events reported, and in which groups?
7. Is there a comparison group, so events can be compared side by side?
8. Is this product being studied under FDA oversight, or is someone offering it for sale outside a trial?

If you have a concern about a regenerative medicine product, see our guide on reporting a side effect or product concern.

Sources

• ClinicalTrials.gov. Adverse Event Data Preparation Checklist (December 2017).
• ClinicalTrials.gov. Glossary: Serious Adverse Event.
• U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies (content current as of April 8, 2024).

Educational Disclaimer and Independence

This article is general educational information about reading clinical research. It is not medical advice, diagnosis, or treatment. It does not recommend any product, procedure, clinic, or study. Talk with a licensed clinician about your own health decisions.

Regenerative Evidence Guide is an independent educational publication. It is not affiliated with any former academy, faculty, conference, clinic, or training program previously connected with this domain. It offers no treatment, training, continuing education, or credentials.